Background and objective: Anti-vascular endothelial growth factor (VEGF) injections are often administered less frequently in real-world treatment of diabetic macular oedema (DMO) than what was studied in clinical trials. This study aims to characterise real-world DMO treatment patterns and the effect of treatment intervals on patient outcomes. Study design/patients and methods: This was a retrospective study of 291 patients with DMO treated with anti-VEGF therapy. 12- and 24-month best visual acuity (BVA) and central subfield thickness (CST) were compared between injection interval groups, which were determined by averaging the two most recent injection intervals. Multiple linear regressions were performed to identify factors associated with injection interval, BVA, and CST. Results: 48.8% of patients received injections less than or equal to every 8 weeks (≤ q8w), 27.5% between every 8 to 12 weeks (q8–12w), and 23.7% greater than every 12 weeks (> q12w). Baseline CST was similar (p = 0.32), but BVA differed significantly in q8–12w patients (p = 0.0095). BVA and CST at 12 months were similar, but q8–12w patients experienced greater 12-month BVA improvement (7.36 ± 12.4 letters) than > q12w patients (1.26 ± 12.3 letters; p = 0.0056). 24-month BVA and CST changes were similar between groups (p = 0.30 and 0.87). Baseline BVA, HbA1c, and sex were associated with 12-month BVA, and baseline BVA and CST were associated with 12-month CST. Conclusion: Many patients experienced improvements in BVA and CST over 12 months of treatment despite receiving less frequent anti-VEGF therapy than recommended in the pivotal trials. The present study showed that extended treatment intervals with bevacizumab were effective in preserving vision of many individuals with high baseline BVA.
Background/Objectives: Anti-VEGF treatment response in DMO has been measured by changes in the central subfield thickness (CST) and best visual acuity (BVA) outcomes at 3 months after initial treatment, termed early or limited early response (ER/LER). This study correlates LER with 12-month BVA, CST, and retinal fluid volumes quantified by a machine learning algorithm on optical coherence tomography (OCT). Subjects/Methods: The study included treatment naïve DMO patients ≥ 18 years with OCT scans at baseline (M0), M3, M6, and M12. The 220 patients were categorized as limited early responders (LER) if they had ≤ 10% CST reduction and/or < 5 ETDRS letter gain at M3. BVA, CST, and subretinal (SRF), intraretinal (IRF), and total retinal (TRF) fluid volumes quantified by a machine learning algorithm were compared between groups and across time. Results: At M12, the anatomic LER (aLER), defined solely by CST, had significantly worse BVA and CST versus the anatomic ER (aER) group (p < 0.001). Retinal fluid M12 outcomes did not significantly vary between all LER and ER groups. No significant BVA, CST, TRF, and IRF variance across time for LER was found (p > 0.1). Conclusions: BVA and CST M12 outcomes vary by aLER/aER status indicating that CST may be a strong predictor of treatment outcomes, while retinal fluid volumes were not predicted by LER status.
Purpose: Assess patient adherence, diurnal intraocular pressure patterns, and correlation with in-office tonometry of home intraocular pressure monitoring (IOP). Patients and Methods: In this prospective cohort study, 75 patients with open-angle disease (150 eyes) were recruited and loaned the iCare HOME2 tonometer (ICH2) after in-person training and instructed to take 6 measurements per day for 10 ± 4 days. Statistical analysis of adherence, diurnal IOP patterns, and correlation with in-office tonometry was conducted. Results: Most patients had good adherence (65% of patients took ≥ 6 measurements per day, median 7.4 measurements/day). However, adherence was poor for a notable minority of patients (19% of patients took less than 2 measurements per day). Patients with low adherence reported difficulty obtaining measurements and desire for more training with the ICH2 device. ICH2 identified diurnal patterns of IOP fluctuation: IOP varied significantly over the 24-hour day (p < 0.0001), and early morning peak IOP at 3 AM decreased significantly throughout the day to minimum mean IOP at 10 PM (p < 0.0001). IOP variance was significantly greater outside of clinic hours (p < 0.0001) and 36% of patients had maximum IOP outside of clinic hours. In-office IOP measurements had significant positive correlation to the closest ICH2 measurement obtained by the patient in time for both Goldman applanation (r2 = 0.35, p < 0.0001) and iCare IC100 (r2 = 0.48, p < 0.0001). Conclusion: ICH2 is clinically useable and effective for detecting out-of-office IOP spikes, diurnal IOP patterns, and IOP variation.
To evaluate outcomes and complications of pars plana vitrectomy (PPV) for nonclearing vitreous hemorrhage (NCVH) secondary to proliferative diabetic retinopathy (PDR) in the small gauge, anti-vascular endothelial growth factor (anti-VEGF) era. Retrospective consecutive case series of patients seen at Cole Eye Institute from 2014-2022 SUBJECTS: 306 eyes undergoing PPV for NCVH. Key inclusion criteria included PPV specifically indicated for NCVH without tractional retinal detachment secondary to diagnosis of DR of any severity. Patients without preoperative documentation or 6 - and 12 -month follow-up visit were excluded. Pertinent data was then manually extracted from the electronic medical record. Descriptive statistics, univariate analysis, and propensity score matched regression analysis was performed. Post-operative vitreous hemorrhage, repeated vitrectomy, and best corrected visual acuity (BCVA) at 12 months. Anti-VEGF was used in 199 of 306 eyes (65.0%) preoperatively with an average number of 1.67 ± 0.8 injections prior to vitrectomy. At 12 months after surgery 94.8% of patients gained or maintained their BCVA. Seventy-five of 306 (24.5%) of patients had a postoperative vitreous hemorrhage with only 48 of 306 (15.6%) requiring a second vitrectomy. Preoperative anti-VEGF injections was not associated with reduced odds of recurrent vitreous hemorrhage, improved 12-month BCVA, nor did it protect against repeat vitrectomy. This study did not find evidence that preoperative anti-VEGF provided significant benefit in visual rehabilitation, reoperation or overall postoperative vitreous hemorrhage in NCVH cases without preoperative evidence of tractional detachment.